WO2019152663A1 - Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer - Google Patents

Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer Download PDF

Info

Publication number
WO2019152663A1
WO2019152663A1 PCT/US2019/016076 US2019016076W WO2019152663A1 WO 2019152663 A1 WO2019152663 A1 WO 2019152663A1 US 2019016076 W US2019016076 W US 2019016076W WO 2019152663 A1 WO2019152663 A1 WO 2019152663A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cancer
cytokine
composition
cell
Prior art date
Application number
PCT/US2019/016076
Other languages
English (en)
Inventor
Sang Woo Park
Yong Man Kim
Jae Seob JUNG
Yong-Hee RHEE
Original Assignee
Nkmax Co., Ltd.
Benedict, Mark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190001981A external-priority patent/KR20190093499A/ko
Priority claimed from KR1020190001983A external-priority patent/KR20190093500A/ko
Priority to AU2019215034A priority Critical patent/AU2019215034C1/en
Priority to EP19746979.4A priority patent/EP3746095A4/fr
Priority to IL276365A priority patent/IL276365B2/en
Priority to CN201980011279.4A priority patent/CN111757745B/zh
Priority to SG11202007221QA priority patent/SG11202007221QA/en
Priority to MX2020008039A priority patent/MX2020008039A/es
Priority to JP2020541915A priority patent/JP7268039B2/ja
Priority to CN202211266361.1A priority patent/CN115710576A/zh
Application filed by Nkmax Co., Ltd., Benedict, Mark filed Critical Nkmax Co., Ltd.
Priority to BR112020015512-8A priority patent/BR112020015512A2/pt
Priority to CA3089853A priority patent/CA3089853A1/fr
Priority to NZ766453A priority patent/NZ766453A/en
Priority to MYPI2020003935A priority patent/MY197176A/en
Priority to RU2020128764A priority patent/RU2780848C2/ru
Priority to US16/523,964 priority patent/US10590385B2/en
Publication of WO2019152663A1 publication Critical patent/WO2019152663A1/fr
Priority to US16/773,888 priority patent/US11066644B2/en
Priority to PH12020551151A priority patent/PH12020551151A1/en
Priority to US17/009,558 priority patent/US12098388B2/en
Priority to AU2021266198A priority patent/AU2021266198A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46432—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Definitions

  • the present disclosure relates to a manufacturing method for high-purity natural killer cells.
  • the human body is protected from pathogens by an immune response, coordinated by the immune system, which is composed of many immune-related cells, chemical mediators, such as cytokines, and the like.
  • Leukocytes especially lymphocytes, play an important role in such an immune system. Lymphocytes are involved in both innate and acquired immunity.
  • Natural killer cells are one type of innate immune cells, which are known to non-specifically kill cancer, recognize and kill viruses, bacteria, and the like, and kill pathogens with enzymes such as perforin and granzyme or by Fas-FasL interaction.
  • a decrease in cancer cell cytotoxicity of these NK cells is associated with the onset of various types of cancer, such as lung cancer (Carrega P, et al., Cancer, 2008: 112: 863-875), liver cancer (Jinushi M, et al., J Hepatol., 2005: 43; 1013-1020), breast cancer (Bauernhofer T, et al., Eur J Immunol., 2003: 33: 119- 124), uterine cancer (Mocchegiani E., et al., Br j Cancer., 1999: 79: 244-250), blood cancer (Tajima F., et al, Lekemia 1996: 10: 478-482), and the like. Accordingly, for cancer therapy, it is desirable to increase the cancer cell cytotoxicity of the NK cells.
  • NK cells In order to obtain the therapeutic effect of K-mediated killing of the cancer cells, a large amount of NK cells having high purity is required, but it is not easy to obtain a large amount of blood from the cancer patient, and of the proportion of NK cells in the blood is small, only about 5 to 20%. Thus, it has been difficult for using the NK cells as an immunotherapeutic agent.
  • NK cells other types (e.g., T cells, B cells, etc.) of immune cells may be present together with the NK cells, and allogenic administration of the NK cells containing T cells may cause a graft versus host disease (GVHD) and allogenic administration of the NK cells containing B cells to blood-type incompatible subjects may cause a passenger B-lymphocyte syndrome, and thus, the anti-cancer effect is not maximized.
  • T cells e.g., T cells, B cells, etc.
  • GVHD graft versus host disease
  • NK cells in addition to expanding and proliferating NK cells, it is desirable to highly maintain the functions of NK cells until the expanded and proliferated NK cells are actually used. As a result, the development of a composition capable of promoting the proliferation of the NK cells, increasing production of cytokines such as TNF-, INF- and GM-CSF derived from the NK cells, and increasing cancer cell cytotoxicity of the NK cells is sought.
  • cytokines such as TNF-, INF- and GM-CSF derived from the NK cells
  • cancer cell cytotoxicity of the NK cells is sought.
  • This application is related to methods of producing high-purity natural killer cells, and a cell therapeutic composition for treating cancer comprising high-purity natural killer cells and cytokines.
  • Any features, structures, or steps disclosed herein can be replaced with or combined with any other features, structures, or steps disclosed herein, or omitted.
  • certain aspects, advantages, and features of the inventions have been described herein. It is to be understood that not necessarily any or all such advantages are achieved in accordance with any particular embodiment of the inventions disclosed herein. No individual aspects of this disclosure are essential or indispensable.
  • a method of producing natural killer cells includes: isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3-/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3-/CD56+ cells with a combination of feeder cells in the presence of a cytokine.
  • PBMCs peripheral blood mononuclear cells
  • isolating at least one of CD56+ cells and/or CD3- /CD56+ cells from the PBMCs is conducted by using at least one of CD56 microbeads and CD3 microbeads.
  • the cytokine is selected from a group consisting of IL-2, IL-21, IL-15, Flt3-L, SCF, IL-7, IL-18, IL-4, type I interferons, GM-CSF, IGF 1, and combinations thereof.
  • the cytokine may be added at a concentration of 50-1000 IU/mL.
  • the combination of feeder cells includes irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV- LCL) cells.
  • the ratio of the irradiated Jurkat cells and the irradiated EBV-LCL cells may be about 1:0.1-5.
  • Each of the irradiated Jurkat cells and the irradiated EBV-LCL cells may be obtained by irradiation of 50-500Gy.
  • the co-culturing may include co-culturing for 1-50 days.
  • the method may further include co-culturing the at least one of CDS 6+ cells and/or CD3-/CD56+ cells with a combination of feeder cells, in the presence of a first cytokine for a first period; and subsequently co-culturing the at least one of CD56+ cells and/or CD3-/CD56+ cells with the combination of feeder cells, in the presence of a second cytokine for a second period.
  • the second cytokine may be added once or more during Day 0-6 of the second period.
  • the second cytokine may be added once or more during the first six days of every fourteen-day cycle during the second period.
  • the first cytokine may be IL-2.
  • the second cytokine may be IL-21.
  • the second cytokine may be added at a concentration of 10-100 ng mL.
  • the at least one of CD56+ cells and/or CD3- /CD56+ cells and the combination of feeder cells is co-cultured with a ratio of about 1 : 1-100 of CD56+ cells and/or CD3-/CD56+ cells to feeder cells.
  • composition made by the method is disclosed.
  • a composition for treating cancer in a patient in need thereof includes: an effective amount of CD56+ natural killer cells derived from peripheral blood, wherein the effective amount is in a range of about 1 x 10 6 to 5 x 10 8 cells per kg of the patient's body weight, and wherein the CD56+ natural killer cells are at least about 90% pure; IL-2 having a concentration of 50-50,000 IU/mL; and a pharmaceutically acceptable carrier.
  • the cytokine may be selected from a group consisting of IL-2, IL-21, IL-15, Flt3-L, SCF, IL-7, IL-18, IL-4, type I interferons, GM-CSF, IGF 1, and combinations thereof.
  • the cytokine may be IL-2.
  • the cytokine may have a concentration of 50-50,000 IU/mL.
  • the cancer is selected from a group consisting of: blood cancer, stomach cancer, pancreatic cancer, cholangiocarcinoma, colon cancer, breast cancer, liver cancer, ovarian cancer, lung cancer, kidney cancer, prostate cancer and neuroblastoma.
  • the composition includes less than about 1% T cells.
  • FIG. 1A illustrates a graph showing cell growth rates of NK cells produced from PBMCs, CD56+ cells, and CD3-/CD56+ cells.
  • FIG. IB illustrates graphs showing cell growth rates of NK cells produced from PBMCs and CDS 6+ cells with or without treating with IL-21.
  • FIG. 2 illustrates a graph showing the purity of CD3-/CD56+ NK cells produced from PBMCs or CD56+ cells with or without treating with IL-21.
  • FIG. 3 illustrates a plate design for analyzing anticancer activity of NK cells.
  • FIG. 4 A illustrates graphs showing the short-term cytotoxicity of NK cells produced from PBMCs and CD56+ cells for various effector cell : target cell (E:T) ratios.
  • FIG. 4B illustrates graphs showing the long-term cytotoxicity of NK cells produced from PBMCs and CD56+ cells against AGS, A549, and MDA-MB-231 cells.
  • FIGS. 5A-5B illustrate graphs showing cell growth rates of NK cells produced by treating with IL-21 during various periods.
  • FIG. 6 illustrates graphs showing cell growth rates of NK cells produced by treating with IL-21 with various concentrations.
  • FIG. 7 A illustrates a graph showing the short-term cytotoxicity of N K cells produced by treating with IL-21 during various periods for various E:T ratios.
  • FIGS. 7B-7C illustrate graphs showing the long-term cytotoxicity of NK cells produced by treating with IL-21 during various periods against AGS, A549, and MDA- MB-231 cells.
  • FIG. 8A illustrates graphs showing the short-term cytotoxicity of NK cells produced by treating with IL-21 with various concentrations for various E:T ratios.
  • FIG. 8B illustrates graphs showing the long-term cytotoxicity of NK cells produced by treating with IL-21 with various concentrations against AGS, A549, and MDA- MB-231 cells.
  • FIG. 9 illustrates graphs showing cell growth rates of NK cells with feeder cell stimulations.
  • FIG. 10A illustrates graphs showing cell growth rates of NK cells produced from PBMCs of a cancer patient with or without treatment of IL-21.
  • FIG. 10B illustrates a graph showing purity of CD3-/CD56+ NK cells produced from PBMCs of a cancer patient with or without treatment of IL-21.
  • FIG. 10C illustrates a graph showing the short-term cytotoxicity of NK cells produced from PBMCs with or without treatment of IL-21 against K562 cells.
  • FIG. 10D illustrates graphs showing the long-term cytotoxicity of K cells produced from PBMCs with or without treatment of IL-21 against AGS, A549, and MDA- MB-231 cells.
  • FIG. 11 illustrates graphs showing survi val rate of NK cells treated with or without IL-2.
  • FIG. 12 illustrates graphs showing the cytotoxicity of NK cells treated with or without IL-2 against various cancer cells at various E:T ratios.
  • FIG. 13 illustrates photographs of remaining NIH:OVCAR-3 cells treated with NK cells treated with or without IL-2.
  • FIG. 14 illustrates photographs of remaining AGS cells treated with NK cells treated with or without IL-2.
  • a method for producing high-purity NK cells without using expensive cytokines has been developed by the inventors.
  • the inventors found that, after CD56+ cells are isolated from peripheral blood mononuclear cells, when the CD56+ cells isolated from peripheral blood mononuclear cells are co-cultured with feeder cells in the presence of cytokines, high-purity CD56+ NK cells could be produced.
  • the present inventors have developed a cell therapeutic composition for treating cancer comprising NK cells which are effectively usable for allogenic therapy.
  • the inventors found that when a specific cytokine was added to CD56+ NK cells isolated from peripheral blood mononuclear cells, high survival rate and high anti-cancer activity were exhibited. Therefore, the inventors sought to develop a method for expanding NK cells and to provide a cell therapeutic composition for the treatment of cancer comprising expanded peripheral blood-derived CD56+ NK cells together with cytokines.
  • a method for producing high-purity NK cells may include: isolating peripheral blood mononuclear cells (PBMCs) from a blood sample ("First Isolation Step”); isolating cells selected from a group consisting of CD56+ cells and CD3-/CD56+ cells from the peripheral blood mononuclear cells (“Second Isolation Step”); and co-culturing the cells selected from a group consisting of CD56+ cells and CD3- /CD56+ cells together with feeder cells in the presence of cytokine (“Culturing Step”).
  • PBMCs peripheral blood mononuclear cells
  • First Isolation Step isolating cells selected from a group consisting of CD56+ cells and CD3-/CD56+ cells from the peripheral blood mononuclear cells
  • Cells co-culturing the cells selected from a group consisting of CD56+ cells and CD3- /CD56+ cells together with feeder cells in the presence of cytokine
  • the CD3-/CD56+ cells produced according to the disclosed method may exhibit not only higher purity and higher anti-cancer activity, but also other distinguished characteristics, such as having different surface markers or activated receptors, for example, one or more from CD16, CD25, CD27, CD28, CD69, CD94/NKG2C, CD94/NKG2E, CD266, CD244, NKG2D, KIR2S, KIR3S, Ly94D, NCRs, IFN-a, IFN- b,CXCR3, CXCR4, CX3CR1, CD62L and CD57, as compared with NK cells produced from peripheral blood mononuclear cells without isolating CD56+ cells.
  • CD16 CD25, CD27, CD28, CD69, CD94/NKG2C, CD94/NKG2E, CD266, CD244, NKG2D, KIR2S, KIR3S, Ly94D, NCRs, IFN-a, IFN- b,CXCR3, CXCR4, CX
  • the "blood sample” may be, but not limited to, whole blood of the peripheral blood or leukocytes isolated from the peripheral blood using leukapheresis.
  • the peripheral blood may be obtained from a normal person, a patient having a risk of cancer, or a cancer patient, but the source of the peripheral blood is not limited thereto.
  • the term "leukapheresis” may refer to a method of selectively removing (isolating) leukocytes from the collected blood and then giving the blood to a patient again, and in some embodiments, the leukocytes isolated by the method may be used without additional methods such as a Ficoll-Hypaque density gradient method.
  • peripheral blood mononuclear cell may be used interchangeably with "PBMC", “mononuclear cell” or “monocyte”, and may refer to a mononuclear cell isolated from the peripheral blood which is generally used for anti-cancer immunotherapy.
  • the peripheral blood mononuclear cells may be obtained from the collected human blood using known methods such as a Ficoll-Hypaque density gradient method.
  • the peripheral blood mononuclear cells may be autologous, but allogenic peripheral blood mononuclear cells may also be used for producing high-purity NK cells for anti-cancer immunotherapy according to methods described herein. Further, in some embodiments, the peripheral blood mononuclear cells may be obtained from a normal person, but the peripheral blood mononuclear cells may be also obtained from a patient having a risk of cancer and/ or a cancer patient.
  • CD56+ cells may be used interchangeably with “CD56+ NK cells”, or “CD56+ natural killer cells”, and the term “CD3- /CD56+ cells” may be used interchangeably with “CD3-/CD56+ NK cells.”
  • the CD56+ cells or CD3-/CD56+ cells may include cells in which CD56 glycoprotein on the cell surface is expressed, or further, cells in which CD3 glycoprotein is not expressed while the CD56 glycoprotein is expressed. Even the same type of immune cells may have differences in CD type attached to the cell surface and expression rate and thus, the functions thereof may be different.
  • the isolating of the CD56+ natural killer cells from the blood sample may be performed by an isolating method using at least one selected from the group consisting of CD56 microbeads and CD3 microbeads, or an isolating method using equipment such as CliniMACSs, a flow cytometry cell sorter, etc.
  • the isolating method using the CD56 microbeads and/or the CD3 microbeads may be performed by adding the CD56 microbeads to PBMCs and then removing non-specific binding, or performed by adding the CD3 microbeads to the PBMCs to remove specific binding and then adding the CD56 microbeads again to remove non- specific binding.
  • T cells or other non-natural killer cells may be removed.
  • cytokine may refer to an immunoactive compound that is usable to induce the peripheral blood mononuclear cells to differentiate into NK cells.
  • the cytokine may be interleukin-2 (IL-2), IL-15, IL- 21, FMS-like tyrosine kinase 3 ligand (Flt3-L), a stem cell factor (SCF), IL-7, IL-18, IL-4, type I interferons, a granulocyte-macrophage colony-stimulating factor (GM-CSF), and an insulin-like growth factor 1 (IGF 1), but not limited thereto.
  • IL-2 interleukin-2
  • IL-15 IL- 21, FMS-like tyrosine kinase 3 ligand (Flt3-L), a stem cell factor (SCF), IL-7, IL-18, IL-4, type I interferons, a granulocyte-macrophage colony-stimulating factor (GM-CSF), and an insulin-like growth factor 1 (IGF 1), but not limited thereto.
  • the cytokine may be used at a concentration of 50- 1,000, 50-900, 50-800, 50-700, 50-600, 50-550, 100-550, 150-550, 200-550, 250-550, 300- 550, 350-550, 400-550, 450-550 IU/mL.
  • Conventional methods of proliferating NK cells utilize high concentrations of various cytokines.
  • two types of feeder cells may be used with the high-purity CD56+ cells, NK cells with high yield and high purity may be proliferated using only low concentrations of one cytokine.
  • feeder cell may refer to a cell that does not divide and proliferate, but has metabolic activity to produce various metabolites and thus, helps the proliferation of target cells.
  • the feeder cells may be at least one selected from the group consisting of irradiated Jurkat cells, irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells, and PBMC, HFWT, RPMI 1866, Daudi, MM- 170, K562 or cells genetically modified by targeting K562 (for example, K562-mbIL-15- 41BB ligand).
  • the feeder cells may be the irradiated Jurkat cells and the EBV-LCL cells.
  • Jurkat cell or “Jurkat cell line” may refer to a blood cancer (immortalized acute T cell leukemia) cell line, which has been developed by Dr. Arthur Weiss of the University of California at San Francisco.
  • Jurkat cells in which various chemokine receptors are expressed and capable of producing IL-2, have not generally been considered as a possible candidate of the feeder cells for anti-cancer immunotherapy because MHC class I, which is a natural killer cell activation inhibitor, is highly expressed on the cell surface thereof.
  • the Jurkat cells may be obtained from the ATCC (ATCC TIB-152).
  • EBV-LCL cell or "EBV-LCL cell line” refers to an Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) (D.M.Koelle et al., J Clin Invest, 1993: 91 : 961-968), which is a B cell line that is made by infecting human B cells with Epstein-Barr virus in a test tube.
  • EBV-LCL cells may be directly prepared and used in a general laboratory by a method of adding cyclosporine A in a process of infecting EBV in the PBMC.
  • the EBV-LCL cell may be prepared by following steps.
  • PBMCs 30 x 10 6 PBMCs are added in 9 mL of a culture medium, the mixture is added in a T 25 culture flask, and then 9 mL of an EBV supernatant is added.
  • 80 ⁇ L of cyclosporine A (50 ⁇ g/mL) is added and then cultured at 37°C. After 7 days of culture, a half of supernatant is removed, a fresh culture medium is added, and then 40 ⁇ L of cyclosporine A is added. The same process may be repeated once every 7 days until 28 days of culture.
  • the cell line may be usable after 28 days of culture, and from this time, the cell line may be cultured in the culture medium without adding cyclosporine A.
  • the Jurkat cells and the EBV-LCL cells may be used as the feeder cells after irradiation.
  • the irradiated Jurkat cells and the irradiated EBV- LCL cells may be included at a content ratio of 1:0.1-5, 1 :0.1-4, 1:0.1-3, 1:0.1-2, 1 :0.1-1.5, 1:0.5-1.5, 1:0.75-1.25, 0.1-5:1, 0.1-4: 1, 0.1-3:1, 0.1-2:1, 0.1-1.5: 1, 0.5-1.5: 1 or 0.75-1.25:1.
  • the irradiated Jurkat cells and the irradiated EBV-LCL cells may be included at a content ratio of 1 : 1.
  • the irradiated Jurkat cells and the irradiated EBV- LCL cells may be obtained by treating with irradiation of 50-500, 50-400, 50-300, 50-200, 50-150, 70-130, 80-120 or 90-1 10 Gy.
  • the irradiated Jurkat cells and/or the irradiated EBV-LCL cells may be obtained by treating Jurkat cells and/or EBV-LCL cells with irradiation of 100 Gy.
  • the culturing may be performed for 1-50, 1-42, 1- 40, 1-35, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15 or 1-14 days.
  • the culturing step may further include following steps: co-culluring with the feeder cells and a first cytokine ("first culturing step”); and further co-cul turing after addi tion of a second cytokine ("second culturing step”)
  • the second culturing step may include adding the second cytokine once or more between day 0-6 of culturing.
  • the second culturing step may include adding the second cytokine once on each of day 0 and day 3 of culturing.
  • the second culturing step may include adding the second cytokine and the feeder cells during the first 6 days of the cycle of 14 days of culturing.
  • the second culturing step may include adding the feeder cells during a 14 days cycle, and adding the second cytokine on day 3 and 6 of each cycle once each.
  • the first cytokine may be IL-2.
  • the second cytokine may be IL-21.
  • the second cytokine may be used at the concentration of 10-1000, 10-500, 10-100, 20-100, 30-100, 40-100, 50- 100 or 10-50 ng/mL.
  • culturing with the addition of the second cytokine once or more during day 0-6 may exhibit superior proliferation and/or anti-cancer activity.
  • culturing with the addition of the feeder cells and the second cytokine for six days in the cycle of 14 days may exhibit superior proliferation and/or anticancer activity.
  • the co-culturing may be performed by including the peripheral blood mononuclear cells and the feeder cells (for example, the Jurkat cells and the EBV-LCL cells) at a mixing ratio of 1 : 1 -100, 1 :1 -90, 1 :1-80, 1 :1-70, 1 : 10-65, 1 :20-65, 1 :30- 65, 1:40-65, 1:50-65 or 1:55-65.
  • the peripheral blood mononuclear cells and the feeder cells for example, the Jurkat cells and the EBV-LCL cells
  • the co-culturing may be performed in a medium and any suitable media generally used for induction and proliferation of the peripheral blood mononuclear cells to the NK cells in the art may be used without a limitation as such a medium.
  • any suitable media generally used for induction and proliferation of the peripheral blood mononuclear cells to the NK cells in the art may be used without a limitation as such a medium.
  • an RPMI-1640, DMEM, x- vivo 10, x-vivo20, or cellgro SCGM medium may be used as such a medium.
  • the culture conditions such as a temperature may follow any suitable culture conditions of the peripheral blood mononuclear cells known in the art.
  • a ratio or purity of the CD56+ NK cells may be 85% or more, 90% or more, or 95% or more, or 98% or more with respect to the whole cells. In some embodiments, within the produced NK cells, a ratio of T cells to whole cells may be 15% or less, 10% or less, 5% or less, 2% or less, 1% or less.
  • a cell therapeutic composition for the treatment of cancer may include peripheral blood derived CD56+ NK cells and a cytokine.
  • peripheral blood-derived may mean that the cells are derived from "whole blood of the peripheral blood” or "leukocytes isolated from the peripheral blood using leukapheresis.”
  • the peripheral blood derived CD56+ NK cells may be used interchangeably with peripheral blood mononuclear cell (PBMC) derived CD56+ NK cells.
  • PBMC peripheral blood mononuclear cell
  • the cytokine may be used at a concentration of 18- 180,000, 20-100,000, 50-50,000, 50-1,000, 50-900, 50-800, 50-700, 50-600, 50-550, 100- 550, 150-550, 200-550, 250-550, 300-550, 350-550, 400-550, 450-550 IU/mL.
  • the cytokine may suppress apoptosis of the NK cells included in the cancer treatment composition and increase an ti-cancer activity of the NK cells.
  • the composition may include IL-2 as the cytokine.
  • the CD56+ NK cells may be obtained as described elsewhere herein.
  • the CD56+ NK cells may be obtained by coculturing with feeder cells (e.g. irradiated Jurkat cells and irradiated EBV-LCL cells).
  • feeder cells e.g. irradiated Jurkat cells and irradiated EBV-LCL cells.
  • the ratio of CD56+ NK cells to whole cells may be 85% or more, 90% or more, 95% or more, or 98% or more.
  • the cancer may be blood cancer, stomach cancer, pancreatic cancer, cholangiocarcinoma, colon cancer, breast cancer, liver cancer, ovarian cancer, lung cancer, kidney cancer, prostate cancer or neuroblastoma, but not limited thereto.
  • the composition may not include T cells, or may include only trace amount of T cells.
  • the ratio of T cells to whole cells in the composition may be less than 15%, less than 10%, less than 5%, less than 2%, less than 1% or less.
  • T cell refers to a lymphocyte derived from thymus, which can "memorize” previously encountered antigens and provide information to B cells, thereby facilitates production of antibody and plays an important role in cell immune system. Since these T cells may distinguish very small differences among different antigens to induce an immune response to allogenic antigens, autologous therapy is possible, but there may be a limit to be used for allogenic therapy. Accordingly, the cell therapeutic composition without T cells may be suitable for allotransplantation.
  • the term "cell therapeutic agent” refers to a medicine which is used for treatment, diagnosis, and prevention through a series of actions, such as proliferating and screening autologous, allogenic, and xenogenic living cells in vitro for restoring functions of cells and tissues or changing biological characteristics of the cells by other methods.
  • the cell therapeutic agents have been regulated as medical products from 1 93 in USA and 2002 in Korea. These cell therapeutic agents may be largely classified into two fields, that are, first, stem cell therapeutic agents for tissue regeneration or recovery of organ functions, and second, immune cell therapeutic agents for regulation of immune responses, such as inhibition of the immune response or enhancement of the immune response in vivo.
  • An administration route of cell therapeutic compositions described herein may be any suitable route as long as the composition reaches a target tissue.
  • the administration may be parenteral administration, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, or intradermal administration, but not limited thereto.
  • the cell therapeutic composition described herein may be formulated in a suitable form together with a pharmaceutically acceptable carrier suitable or generally used for cell therapy.
  • a pharmaceutically acceptable carrier suitable or generally used for cell therapy.
  • the pharmaceutically acceptable carrier may include, for example, parenteral administration carries such as water, suitable oils, saline, aqueous glucose and glycol, and the like, and further include stabilizers and preservatives.
  • the suitable stabilizer includes an antioxidant such as sodium hydrogen sulfite, sodium sulfite, or ascorbic acid, sucrose, albumin, or the like.
  • the suitable preservative includes DMSO, glycerol, ethylene glycol, sucrose, trehalose, dextrose, polyvinylpyrrolidone, or the like.
  • the cell therapeutic composition may also be administered by any device in which the cell therapeutic agent may move to the target cell.
  • the cell therapeutic composition may include a therapeutically effective amount of cell therapeutic agent for treatment of diseases.
  • therapeutically effective amount means an amount of an active ingredient or a cell therapeutic composition which induces biological or medical responses in tissue systems, animals, or humans which are considered by researchers, veterinarians, physicians, or other clinicians, and includes an amount of inducing alleviation of symptoms of diseases or disorders to be treated. It will be apparent to those skilled in the art that the cell therapeutic agent included in the cell therapeutic composition may be changed according to a desired effect.
  • the optimal content of the cell therapeutic agent may be easily determined by those skilled in the art, and may be adjusted according to various factors including a type of disease, severity of the disease, contents of other ingredients contained in the composition, a type of formulation, and an age, a weight, a general health condition, a gender, and a diet of a patient, an administration time, an administration route, a secretion ratio of the composition, a treatment period, and simultaneously used drugs. It is important to include an amount capable of obtaining a maximum effect by a minimum amount without side effects by considering all of the factors.
  • the cell therapeutic composition may include a cell therapeutic agent of 1 x 10 6 to 5 x 10 8 cells per kg of body weight.
  • a method for preventing or treating cancer comprising administering a cell therapeutic composition for anti-cancer including peripheral blood-derived CD56+ natural killer cells and cytokines to a subject.
  • subject refers to a mammal which is a subject for treatment, observation, or testing, and preferably, a human.
  • the subject may be a patient of blood cancer, stomach cancer, pancreatic cancer, cholangiocarcinoma, colon cancer, breast cancer, liver cancer, ovarian cancer, lung cancer, kidney cancer, prostate cancer or neuroblastoma, but not limited thereto.
  • the cell therapeutic composition in the case of an adult, may be administered once to several times a day.
  • the cell therapeutic composition may be administered every day or in a 2-180 day interval, the cell therapeutic agent included in the composition may include 1 x 10 6 to 1 x 10 11 peripheral blood-derived CDS 6+ natural killer cells, for example, about 1 x 10 6 to 1 x 10 8 NK cells per kg of body weight.
  • the peripheral blood-derived CD56+ natural killer cells in the cell therapeutic composition are at least about 90% pure.
  • the cytokine is IL-2 at a concentration ranging from about 50 - 50,000 IU/ml.
  • the cell therapeutic composition of the present invention may be administered by any suitable method, such as administration through a rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, percutaneous, topical, intraocular, or intradermal route.
  • the NK cells included in the composition may be allogenic, i.e. obtained from a person other than the subject being treated.
  • the person may be a normal person or a cancer patient.
  • the NK cells included in the composition may be autologous, i.e. obtained from the subject being treated.
  • the NK cells disclosed herein and the cell therapeutic composition including the NK cells disclosed herein may be used for treating disease or condition other than cancer. It has been reported that NK cells plays an important role in the regulation of immune system, for example, by regulating of T-cells, thus the cell therapeutic composition having the NK cells may be administered to treat conditions associated with the immune system.
  • the cell therapeutic composition may be administered to treat neurodegenerative disorders (e.g. Alzheimer's disease and Parkinson's disease) or autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, SLE, Sjogren's syndrome, systemic sclerosis).
  • neurodegenerative disorders e.g. Alzheimer's disease and Parkinson's disease
  • autoimmune diseases e.g. rheumatoid arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, SLE, Sjogren's syndrome, systemic sclerosis.
  • the present invention relates to a method of producing natural killer cells.
  • the present invention relates to a cell therapeutic composition for anticancer comprising peripheral blood-derived CD56+ NK cells and cytokines.
  • composition of the present invention includes high-purity natural killer cells with minimal (e.g., less than about 1%) T cells, and thus the composition may be effectively used for allogenic therapy as well as autologous therapy.
  • CD56+ cells and CD3-/CD56+ cells were isolated from PBMCs by the following method. First, the PBMCs were isolated from the blood using a Ficoll-Hypaque density gradient method and then the cells were counted.
  • the counted PBMCs were added with a MACS buffer (lx PBS+0.5% HSA) and suspended, and added with CD56 microbeads (Miltenyi Biotec) to be 1 to 20 ⁇ L per 1.0 x 10 7 PBMCs, and then incubated at 2 to 8°C for 5 to 30 minutes. After incubation, the MACS buffer was added and mixed, and then the mixture was centrifuged (600 x g) to precipitate the cells. After centrifugation, a supernatant was removed, and the cells were suspended by adding the MACS buffer and added in a column connected to a MACS separator. The MACS buffer passed through the column to remove non-specific binding. The column was separated from the MACS separator and transferred to a 15 mL conical tube, and then added with the MACS buffer to isolate CD56+ cells attached to the column.
  • MACS buffer lx PBS+0.5% HSA
  • Example 1-2 Preparation for producing CD3-/CD56+ cells
  • the counted PBMCs were added with a MACS buffer (lx PBS ⁇ 0.5% HSA) and suspended, and added with CD3 microbeads (Miltenyi Biotec) to be 1 to 20 ⁇ L per 1.0 x 10 7 PBMCs, and then incubated at 2 to 8°C for 5 to 30 minutes. After incubation, the MACS buffer was added and mixed, and then the mixture was centrifuged (600 x g) to precipitate the cells. After centrifugation, a supernatant was removed, and the cells were suspended by adding the MACS buffer and added in a column connected to a MACS separator. The MACS buffer passed through the column to collect CD3- cells.
  • MACS buffer lx PBS ⁇ 0.5% HSA
  • the collected CD3- cells were added with a MACS buffer (lx PBS+0.5% HSA) and suspended, and added with CD56 microbeads (Miltenyi Biotec) to be 1 to 20 ⁇ L per 1.0 x 10 7 CD3- cells, and then incubated at 2 to 8°C for 5 to 30 minutes. After incubation, the MACS buffer was added and mixed, and then the mixture was centrifuged (600 x g) to precipitate the cells. After centrifugation, a supernatant was removed, and the cells were suspended by adding the MACS buffer and added in a column connected to a MACS separator. The MACS buffer passed through the column to remove non-specific binding. The column was separated from the MACS separator and transferred to a 15 mL conical tube, and then added with the MACS buffer to isolate CD3-/CD56+ cells attached to the column.
  • MACS buffer lx PBS+0.5% HSA
  • Example 1-3 Production of NK cells using the CD56+ cells and CD3-/CD56+ cells
  • the CD56+ cells or the CD3-/CD56+ cells isolated from the PBMCs as in Examples 1-1 and 1-2 were added in a RPM1-1640 medium containing FBS 10% added with IL-2 at a concentration of 500 IU/mL together with prepared combination of feeder cells (Jurkat cells and EBV-LCL cells) irradiated with 100 Gy radiation and then co-cultured in an incubator at 37°C and 5% CO 2 .
  • the ratio of (CD56+ cells and/or CD3-/CD56+ cells):(Jurkat cells):(EBV-LCL cells) was about 1:30:30.
  • the Jurkat cells may be obtained from ATCC (ATCC TIB- 152), and the EBV-LCL cells were prepared by the following method: 30 x 10 6 PBMCs were added in 9 mL of a culture medium, the mixture was added in a T 25 culture flask, and then 9 m of an EBV supernatant was added. 80 ⁇ L of cyclosporins A was added and then cultured at 37°C. After 7 days of culture, a half of supernatant was removed, a fresh culture medium was added, and then 40 of cyclosporine A was added. The same process as the 7th day was repeated once every 7 days until 28 days of culture. The cell line was usable after 28 days of culture, and from this time, the cell line was cultured in the culture medium without adding cyclosporine A.
  • NK cells were produced using same method of Example 1 (1-1 to 1-3), except for adding IL-2 (500 IU/mL) and IL-21 (50ng/mL) instead of IL-2 (500 IU/mL).
  • PBMCs were isolated from the blood using a Ficoll-Hypaque density gradient method.
  • the PBMCs were added in a RPMI-1640 medium containing FBS 10% added with IL-2 at a concentration of 500 IU/mL together with prepared feeder cells (Jurkat cells and EBV-LCL cells) irradiated with 100 Gy radiation and then co-cultured in an incubator at 37°C and 5% CO 2 .
  • NK cells were produced using same method of Comparative Example 1, except for adding IL-2 (500 IU/mL) and IL-21 (50ng/mL) instead of IL-2 (500 IU/mL).
  • NK cells were produced using similar methods of Comparative Examples 1&2, respectively, except for that a ratio of PBMC: (Jurkat cells): (EBV-LCL cells) was 1:0.5:0.5.
  • FIG. 1A illustrates the fold increase of NK cells during the culture.
  • the CD56+ NK cells (CD56+ and CD3-/CD56+) of Example 1 were proliferated 2675 and 1903 times respectively on Day 17 compared to Day 0, while the PBMC cells of Comparative Example 1 was proliferated 1768 times on Day 17 compared to Day 0.
  • FIG. IB illustrates the fold increase and the population doubling level (PDL) of NK cells.
  • the PBMCs of Comparative Example 1 (PBMC w/o IL-21) and Comparative Example 2 (PBMC w/ IL-21) were proliferated 243 and 1248 times respectively compared to Day 0, while the CD56+ NK cells of Example 1 (CD56 w/o IL-21) and Example 2 (CD56 w/ IL-21) were proliferated 2990 and 20434 times respectively compared to Day 0.
  • NK cells of Examples 1, 2 and Comparative Examples 1, 2 were washed once with a FACS staining buffer and suspended in 100 ⁇ L, and then stored at 2 to 8°C for 20 to 30 minutes under a dark condition after mixing with a monoclonal antibody binding with fluorescence. After one additional washing, the cells were suspended in 300 to 500 ⁇ L of the FACS staining buffer and then 10,000 to 100,000 cells per tube were obtained and analyzed by using a CD56-FITC/CD3-PE/CD20-PerCP5/CD14-APC panel of a flow cytometer.
  • the purity of the CD56+ NK cells was defined as a ratio of cells introduced in a CD3-/CD56+ region after FSC/SSC gating, and it was further confirmed that CD20 and CD 14 were not expressed in the cells in the CD3-/CD56+ region.
  • K562 cells were prepared by subculturing K562 cells suspended in a RPMI 1640 medium containing FBS 10%, at 37 ⁇ 1°C at an interval of three days, for 7 days or more.
  • the prepared K562 cells were suspended in the RPMI- 1640 medium at a concentration of 1.0 x 10 6 cells/mL, and added with a fluorescent material (Calcein-AM) at a concentration of 4 ⁇ .
  • the K562 cells were stained at 37 ⁇ 1°C for 30 minutes, and then inverted at an interval of ten minutes.
  • the K562 cells stained with the fluorescent material were centrifuged at 3,300 rpm for 3 minutes, washed three times, and then suspended in an SNK medium containing FBS 10%, at a ratio of 1.0 x 10 6 cells/mL.
  • the K562 cells were inoculated into a round bottom microwell plate (96-well) in an amount of 1.0 x 10 4 cells per well.
  • NK cells of the Experimental Example 1 (effector cells) on the 14 to 20th days of culture were suspended and diluted in a RPMI- 1640 medium containing FBS 10% at ratios of 1.0 x 10 6 cells/mL, 3.0 x 10 5 cells/mL, 1.0 x 10 5 cells/mL and 0.5 x 10 5 cells/mL, respectively.
  • the diluted effector cells were inoculated into the plate inoculated with the target cells (the K562 cells) at a concentration of 100 ⁇ L per well for three wells each (triplication), respectively.
  • ratios of the effector cells and the target cells are shown in Table 2 below.
  • the plate design used in the present experiment is shown in FIG. 3, in a negative control group (Spontaneous), fluorescence-stained living K562 cells were added, and in a positive control group (Maximum release), the K562 cells were completely killed using TX-100 and exhibited a maximum fluorescence.
  • the plate inoculated with the target cells and the effector cells was centrifuged at 1000 rpm for 5 minutes, cultured at 37 ⁇ 1°C for 3 to 4 hours, and then centrifuged again at 1,000 rpm for 5 minutes. After centrifugation, 80 ⁇ L of a supernatant was transferred to a black plate (96-well), and then a fluorescence amount was measured using a fluorescence microplate reader and the cytotoxicity against cancer cells was calculated using Equation 1 below.
  • FIG. 4A and Table 3 below show % of lysis of K562 cells at various E:T ratio. As illustrated in FIG. 4A and Table 3 below, as compared with Comparative Example 3 (PBMCs w/o IL-21) and Comparative Example 4 (PBMCs w/ IL-21), the CD56+ cells cultured according to Example 1 (CD56+ w/o IL-21) and Example 2 (CD56+ w/ IL-21) exhibited higher anti-cancer activity. Table 3
  • A549 lung cancer, ATCC® CRL-185TM
  • MDA-MB0231 breast cancer
  • ATCC® HTB-26TM were used as solid tumor cell lines.
  • Each solid tumor cells were tagged with green-fluorescent marker using CYTO-1D® Green long-term tracer kit (Enzo Life Sciences Inc.), inoculated on a plate, and cultured for 24 hours. Next day, NK cells and cancer cells were reacted for 48 hours in 0.5:1 ratio. After 48 hours, cytotoxicity was confirmed by measuring the number of cells exhibiting green-fluorescence using flow cytometer.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 (50ng/mL) during Day 0-6 (DO-6 group), Day 6-10 (D6-10 group), Day 10-14 (Dl 0-14 group), or Day 14-17 (D-14-17 group), and the proliferative ability of the CD56+ NK cells were compared using the method according to Experimental Example 1.
  • NK cells were treated with IL-21: for the DO-6 group, twice, on Day 0 and 3; for the D6-10 group, once, on Day 6; for the D10-14 group, once, on Day 10; for the D14- 17 group, once, on Day 14.
  • IL-21 for a control group, NK cells were not treated with IL-21.
  • the D10-14 group and the D14-17 group did not exhibit significant difference in proliferative ability as compared with the control group, while the DO-6 group and the D6-10 group exhibited increased proliferation ability as compared with the control group. Especially, the DO-6 group exhibited the greatest expansion fold increase.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 (50 ng mL) during Day 0-3 (DO-3 group), Day 3-6 (D3-6 group), or Day 0-6 (DO-6 group), and the proliferative ability of the CDS 6+ NK cells were compared using the method according to Experimental Example 1.
  • NK cells were treated with IL-21 : for the D0-3 group, once, on Day 0; for the D3-6 group, once, on Day 3; for the DO-6 group, twice, on Day 0 and 3.
  • IL-21 for the D0-3 group, once, on Day 0; for the D3-6 group, once, on Day 3; for the DO-6 group, twice, on Day 0 and 3.
  • IL-21 for a control group, NK cells were not treated with IL-21.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 with a concentration of 0 ng/mL, 10 ng/mL, 30 ng/mL, 50 ng/mL or 100 ng/mL twice, and the proliferative ability of the CD56+ NK cells were compared using the method according to Experimental Example 1.
  • the NK cells exhibited greater expansion fold as compared with the NK cells with no IL-21 treatment, and the expansion fold of the NK cells increased as the concentration of IL-21 increases between 10 ng/mL-50 ng/mL.
  • the NK cells did not exhibit significant difference in expansion from the NK cells treated with IL-21 with a concentration of 50 ng/mL.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 (50ng/mL) during Day 0-6 (DO-6 group), Day 6-10 (D6-10 group), Day 10-14 (D10-14 group), or Day 14-17 (D-14-17 group), and the cytotoxicity of the
  • NK cells against blood cancer cells were compared using the method according to Experimental Example 3.
  • NK cells were treated with IL-21: for the DO-6 group, twice, on Day 0 and 3; for the D6-10 group, once, on Day 6; for the Dl 0-14 group, once, on Day 10; for the D 14- 17 group, once, on Day 14.
  • IL-21 for the DO-6 group, twice, on Day 0 and 3; for the D6-10 group, once, on Day 6; for the Dl 0-14 group, once, on Day 10; for the D 14- 17 group, once, on Day 14.
  • NK cells were not treated with IL-21.
  • A549 lung cancer, ATCC® CRL-185TM
  • MDA-MB0231 breast cancer
  • ATCC® HTB-26TM were used as solid tumor cell lines.
  • the NK cells with IL-21 treatment during an earlier stage of the culture (the DO-6 group) exhibited the greatest anti-cancer activity against all three types of solid tumor cells.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 (50 ng/mL) during Day 0-3 (D0-3 group), Day 3-6 (D3-6 group), or Day 0-6 (D0-6 group), and the cytotoxicity of the CDS 6+ NK cells against solid tumor cells were compared using the method according to Experimental Example 3.
  • AGS stomach cancer, ATCC® CRL-1739TM
  • A549 lung cancer, ATCC® CRL-185TM
  • MB0231 (breast cancer, ATCC® HTB-26TM) were used as solid tumor cell lines.
  • NK cells were treated with IL-21: for the D0-3 group, once, on Day 0; for the D3-6 group, once, on Day 3; for the DO-6 group, twice, on Day 0 and 3.
  • IL-21 for the D0-3 group, once, on Day 0; for the D3-6 group, once, on Day 3; for the DO-6 group, twice, on Day 0 and 3.
  • NK cells were not treated with IL-21.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 with a concentration of 0 ng/mL, 10 ng/mL, 30 ng/mL, 50 ng/mL or 100 ng/mL twice, and the cytotoxicity of the CD56+ NK cells against blood cancer cells
  • NK cells treated with IL-21 exhibited greater cytotoxicity as compared with the NK cells with no IL-21 treatment, when treated with IL-21 with a concentration of 100 ng/mL, the NK cells did not exhibit significant difference in expansion from the NK cells not treated with IL-21.
  • CD56+ NK cells were produced according to the method of Example 1, but treated with IL-21 with a concentration of 0 ng/mL, 10 ng/mL, 30 ng/mL, 50 ng/mL or 100 ng/mL twice, and the cytotoxicity of the CD56+ NK cells against solid tumor cells (K562 cells, CCL-243TM) were compared using the method according to Experimental Example 3.
  • AGS stomach cancer, ATCC® CRL-1739TM
  • A549 lung cancer, ATCC® CRL-185TM
  • MDA-MB0231 breast cancer, ATCC® HTB-26TM
  • NK cells during the culture were treated with feeder cells in an interval of 14 days, and the expansion of NK cells were monitored for 42 days.
  • NK cells were treated with IL-21 (50 ng/mL) twice in 3 days interval, during a six days period from each treatment with feeder cells (Day 0-6, 14-20, 28-34).
  • CD56+ NK cells were produced according to the method of Example 1 for 17 days, except that PBMCs of colorectal cancer patients was used. The proliferative ability and the purity of the produced NK cells was measured using methods according to Experimental Examples 1 and 2.
  • the NK cells were treated with IL-21 with a concentration of 50 ng mL twice (Day 0 and Day 3 of culture), to confirm the effect of IL-21 treatment.
  • the number of the NK cells not treated with IL- 21 increased 8 times from Day 0, while when treated with IL-21, the number of the NK cells increased 1461 times from Day 0.
  • the purity of the NK cells not treated with IL-21 was only 84.2%, while when treated with IL-21, the purity of the NK cells was 99.19%.
  • cytotoxicity of the NK cells treated with IL-21, and NK cells not treated with IL-21 against blood cancer cells were compared using the method according to Experimental Example 3. As illustrated in FIG. IOC, the NK cells treated with IL-21 exhibited greater anti-cancer activity as compared with the NK cells not treated with IL-21.
  • ATCC® CRL-1739TM A549 (lung cancer, ATCC® CRL-185TM), and MDA-MB-231 (breast cancer, ATCC® HTB-26TM) were used as solid tumor cell lines.
  • FIG. 10D the NK cells treated with IL-21 exhibited greater anti-cancer activity as compared with the NK cells not treated with IL-21.
  • the CD56+ NK cells on the 14th to 20th days of culture were washed three times and then suspended in a base compound (physiological saline and Hartman's solution) containing 1 % albumin to be 2 x 10 7 /mL.
  • the cells were stored at 4°C for 48 hours and then the cell survival rate was measured.
  • the CD56+ NK cells were washed and suspended in a base compound containing 1 % albumin (physiological saline, and Hartmann's solution or phosphate buffered saline), and then added with IL-2 at a concentration of 500 IU/mL. After being kept in 4 °C for 48 hours, cell survival rate was measured.
  • a base compound containing 1 % albumin physiological saline, and Hartmann's solution or phosphate buffered saline
  • a cut-off was determined by setting a test tube which was not stained with the Annexin V-FITC and the 7-AAD as a negative control, and the survival rate was represented by a percentage of fraction of cells in which the Annexin V-FITC or the 7-AAD was negative.
  • NK cells With respect to each of the NK cells cultured in a CO 2 incubator according to Examples 1, 2 on Day 6 of culture, cells were inoculated into a 350 mL bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and further cultured for 4 days. On Day 10 of culture, the cells were inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 4 days. Finally, on Day 14 of culture, the cells were inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 3 to 6 days.
  • the cancer cell lines were prepared by suspending under the following conditions, and sub-culturing at 37 ⁇ 1°C at an interval of three days for 1 week or more:
  • CCRF-SB blood cancer, ATCC® CCL-120TM
  • AGS stomach cancer, ATCC® CRL-1739TM
  • MIA-PACA2 pancreatic cancer, ATCC® CRL-1420TM
  • SNU245 cholangiocarcinoma, KCLB No. 00245
  • HCT15 colon cancer, ATCC® CCL-225TM
  • NIH:OVCAR-3 ovarian cancer, ATCC® HTB-161TM
  • MDA-MB-231 (breast cancer, ATCC® HTB-26TM): DMEM medium + 10% FBS.
  • the cancer cell lines (except for a blood cancer cell line) during culturing were detached from a culture dish using trypsin and suspended in the medium to be 5 x 10 4 /mL, and then inoculated into a 24- well plate by 1 mL per well and attached for one day.
  • the blood cancer cell line which was a suspended culture cell, was labeled with green fluorescence, suspended in the medium to be 5 x 10 4 /mL, and inoculated into a 24-well plate by 1 mL per well.
  • the plate inoculated with the effector cells and the target cells was cultured at 37 ⁇ 1°C for 1 to 3 days, and at this time, in order to observe whether anti-cancer activity is increased by IL-2, 500 IU/ml of IL-2 was further added to an experimental group.
  • 500 IU/ml of IL-2 was further added to an experimental group.
  • the CD56+ NK cells effector cells
  • the cells were washed with RPMI three times to remove the CD56+ NK cells present in the suspended form, and then the cancer cell lines remaining in the wells were detached using trypsin, stained with trypan blue and counted. Subsequently, the plate inoculated with the target cells and the effector cells was cultured at 37 ⁇ 1°C for 1 to 3 days, and then the cells labeled with green fluorescence present in the 24 wells were counted using a flow cytometer.
  • CD56+ NK cells were added in the 24-well plate to which NIH:OVCAR-3 (ovarian cancer, ATCC® HTB-161TM) cells was attached among the cancer cell lines to observe the cytotoxicity, and ratios of target cells (cancer cell lines) and effector cells (CD56+ NK cells) were shown in Table 8 below.
  • NIH:OVCAR-3 ovarian cancer, ATCC® HTB-161TM
  • the plate inoculated with the effector cells and the target cells was cultured at 37 ⁇ 1°C for 1 days, and, in order to observe whether anti-cancer activity is increased by IL-2, 500 lU/ml of IL-2 was further added to an experimental group. In a negative control group, the CD56+ NK cells were not added and there was no anti-cancer activity reaction.
  • the cancer cell cytotoxicity was increased when cancer cell lines were treated together with IL-2(+ IL2), as compared to when cancer cell lines were treated with only the CD56+ NK cells(-IL2).
  • CD56+ NK cells were added in the 24-well plate to which AGS (stomach cancer, ATCC® CRL-1739TM) cells was attached among the cancer cell lines to observe the cytotoxicity, and ratios of target cells (cancer cell lines) and effector cells (CDS 6+ NK cells) were shown in Table 9 below.
  • AGS stomach cancer, ATCC® CRL-1739TM
  • the plate inoculated with the effector cells and the target cells was cultured at 37 ⁇ 1 °C for 1 days, and, in order to observe whether anti-cancer activity is increased by IL-2, 500 IU/ml of IL-2 was further added to an experimental group. In a negative control group, the CD56+ NK cells were not added and there was no anti-cancer activity reaction.
  • the cancer cell cytotoxicity was increased when cancer cell lines were treated together with IL-2 (+IL2), as compared to when cancer cell lines were treated with only the CD56+ NK cells (-IL2).
  • CD56+ NK cells are produced according to the method of Examples 1, 2 and Comparative Examples 1, 2 for 17 days, except that PBMCs of colorectal cancer patients is used.
  • PBMCs of colorectal cancer patients is used.
  • cells are inoculated into a 350 mL bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 3 to 6 days.
  • mice Animal models of human cancer are constructed by xenograft of human cancer cell line into mice. Following human cancer cell lines are used: AGS (stomach cancer), MIA-PACA2 (pancreatic cancer), SNU245 (cholangiocarcinoma), HCT15 (colon cancer) and NIH:OVCAR-3 (ovarian cancer), and MDA-MB-231 (breast cancer). After xenograft of cancer, the mice are grouped randomly and marked. The control group is injected 200 ⁇ L of Hartmann's solution into the vein of tail.
  • AGS stomach cancer
  • MIA-PACA2 pancreatic cancer
  • SNU245 cholangiocarcinoma
  • HCT15 colon cancer
  • NIH:OVCAR-3 ovarian cancer
  • MDA-MB-231 breast cancer
  • the NK cell-treated (+IL-2) group is injected five times with 1 x 10 7 NK cells/200 ⁇ L and 500 IU/mL of IL-2 at 2-3-day intervals from 1 week after xenograft of cancers into the vein of tail.
  • the NK cell-treated (- IL-2) group is injected five times with 1 x 10 7 NK cells/200 ⁇ L at 2-3-day intervals from 1 week after xenograft of cancers into the vein of tail.
  • mice are tested for body weight and tumor volume three time a week. Length of major axis and minor axis are measured using a caliper and tumor volume is determined according to the following equation (Equation 3).
  • Tumor Volume (mm 3 ) (length of major axis (mm)) x (length of minor axis (mm)) 2 x 0.5
  • the NK cell-treated (-IL-2) group exhibits a reduction in tumor growth after 8 weeks treatment of approximately 50% compared to the control group based on luciferase images for each cancer type.
  • the NK cell-treated (+ IL-2) group exhibits a further reduction in tumor growth of approximately 60% compared to the control group for each cancer type.
  • CD56+ NK cells are produced according to the method of Examples 1, 2 and Comparative Examples 1, 2 for 18 days, except that PBMCs of colorectal cancer patients is used.
  • PBMCs of colorectal cancer patients is used.
  • cells are inoculated into a 350 mL bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 3 to 6 days.
  • the colorectal cancer patients are grouped randomly and marked.
  • the control group is not injected with NK cells.
  • the NK cell-treated (+IL-2) group is injected three times with 1-3x10 7 NK cells/ per kg of body weight and 500 IU/mL of IL-2 at six week intervals intravenously.
  • the NK cell-treated (-IL-2) group is injected six times with 1 -3x 10 7 NK cells/ per kg of body weight at six week intervals intravenously.
  • CD56+ NK cells are produced according to the method of Examples 1, 2 and Comparative Examples 1, 2 for 18 days, except that PBMCs of colorectal cancer patients is used.
  • PBMCs of colorectal cancer patients is used.
  • cells are inoculated into a 350 mL bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1 .0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 3 to 6 days.
  • Alzheimer's Disease patients are grouped randomly and marked.
  • the control group is not injected with NK cells.
  • the NK cell-treated group is injected six times with l-3x l0 7 NK cells/ per kg of body weight and 500 IU/mL of IL-2 at weekly intervals intravenously.
  • Cognitive function of the patient are monitored at 1 , 3, 6, 12 months. After 12 months, the NK cell-treated group exhibits improved cognitive function.
  • NK cells are produced according to the method of Examples 1, 2 and Comparative Examples 1, 2 for 18 days, except that PBMCs of colorectal cancer patients is used.
  • PBMCs of colorectal cancer patients is used.
  • NK cells cultured in a CO 2 incubator according to Examples 1, 2 and Comparative Examples 1, 2 on Day 6 of culture in a T 25 culture flask, cells are inoculated into a 350 mL bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and further cultured for 4 days.
  • the cells On Day 10 of culture, the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 4 days.
  • the cells are inoculated into a 1 L bag on the basis of the cell number of 1.0 x 10 5 to 2.0 x 10 6 /mL and then further cultured for 3 to 6 days.
  • Multiple sclerosis patients are grouped randomly and marked.
  • the control group is not injected with NK cells.
  • the NK cell-treated group is injected six times with 1- 3x10 7 NK cells/ per kg of body weight and 500 IU/mL of IL-2 at weekly intervals intravenously.
  • Cognitive function of the patient are monitored at 1, 3, 6, 12 months. After 12 months, the NK cell-treated group exhibits improved cognitive function.
  • Conditional language such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments.
  • the term "generally” as used herein represents a value, amount, or characteristic that predominantly includes or tends toward a particular value, amount, or characteristic.
  • the term “generally uniform” refers to a value, amount, or characteristic that departs from exactly uniform by less than 20%, less than 15%, less than 10%, less than 5%, less than 1%, less than 0.1%, and less than 0.01%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de production de cellules tueuses naturelles. Le procédé comprend l'isolement de cellules mononucléées du sang périphérique (PBMC) à partir d'un échantillon de sang ; l'isolement de cellules CD56+ et/ou de cellules CD3-/CD56+ à partir des PBMC ; et la co-culture des cellules CD56+ et/ou des cellules CD3-/CD56+ avec une combinaison de cellules nourricières en présence d'une cytokine. La présente invention concerne également une composition pour le traitement du cancer. La composition comprend les cellules tueuses naturelles CD56+ produites par le procédé décrit et une cytokine.
PCT/US2019/016076 2018-02-01 2019-01-31 Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer WO2019152663A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
MYPI2020003935A MY197176A (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer
RU2020128764A RU2780848C2 (ru) 2018-02-01 2019-01-31 Способ получения природных клеток-киллеров и композиция для лечения рака
BR112020015512-8A BR112020015512A2 (pt) 2018-02-01 2019-01-31 método de produção de células exterminadoras naturais e composição para tratamento de câncer
IL276365A IL276365B2 (en) 2018-02-01 2019-01-31 A method for the production of natural killer cells and a preparation for cancer treatment
CN201980011279.4A CN111757745B (zh) 2018-02-01 2019-01-31 产生天然杀伤细胞的方法和用于治疗癌症的组合物
SG11202007221QA SG11202007221QA (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer
MX2020008039A MX2020008039A (es) 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
JP2020541915A JP7268039B2 (ja) 2018-02-01 2019-01-31 がん治療のためのナチュラルキラー細胞および組成物の製造方法
CN202211266361.1A CN115710576A (zh) 2018-02-01 2019-01-31 产生天然杀伤细胞的方法和用于治疗癌症的组合物
AU2019215034A AU2019215034C1 (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer
EP19746979.4A EP3746095A4 (fr) 2018-02-01 2019-01-31 Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer
CA3089853A CA3089853A1 (fr) 2018-02-01 2019-01-31 Procede de production de cellules tueuses naturelles et composition pour le traitement du cancer
NZ766453A NZ766453A (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer
US16/523,964 US10590385B2 (en) 2018-02-01 2019-07-26 Method of producing natural killer cells and composition for treating cancer
US16/773,888 US11066644B2 (en) 2018-02-01 2020-01-27 Method of producing natural killer cells and composition for treating cancer
PH12020551151A PH12020551151A1 (en) 2018-02-01 2020-07-30 Method of producing natural killer cells and composition for treating cancer
US17/009,558 US12098388B2 (en) 2018-02-01 2020-09-01 Method of producing natural killer cells and composition for treating cancer
AU2021266198A AU2021266198A1 (en) 2018-02-01 2021-11-08 Method of producing natural killer cells and composition for treating cancer

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
KR20180012938 2018-02-01
KR10-2018-0012942 2018-02-01
KR10-2018-0012938 2018-02-01
KR20180012942 2018-02-01
KR1020190001981A KR20190093499A (ko) 2018-02-01 2019-01-07 자연살해세포의 생산방법
KR10-2019-0001981 2019-01-07
KR10-2019-0001983 2019-01-07
KR1020190001983A KR20190093500A (ko) 2018-02-01 2019-01-07 Cd56+ 자연살해세포를 포함하는 항암용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/523,964 Continuation US10590385B2 (en) 2018-02-01 2019-07-26 Method of producing natural killer cells and composition for treating cancer

Publications (1)

Publication Number Publication Date
WO2019152663A1 true WO2019152663A1 (fr) 2019-08-08

Family

ID=67479477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/016076 WO2019152663A1 (fr) 2018-02-01 2019-01-31 Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2019152663A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114867847A (zh) * 2019-11-20 2022-08-05 吉爱希公司 用于培养自然杀手细胞的组合物及使用其来生产自然杀手细胞的方法
CN115197909A (zh) * 2021-04-12 2022-10-18 北京和斯瑞生物技术有限公司 一种nk细胞的体外培养方法
US11504396B2 (en) 2016-12-21 2022-11-22 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
CN117106718A (zh) * 2023-09-21 2023-11-24 深圳泽医细胞治疗集团有限公司 一种靶向肺部的nk细胞培养基、培养方法与应用
US12098388B2 (en) 2018-02-01 2024-09-24 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140120072A1 (en) * 2011-06-24 2014-05-01 Tella, Inc Method for amplifying nk cells
WO2015154012A1 (fr) * 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations
WO2017037083A1 (fr) * 2015-09-04 2017-03-09 Miltenyi Biotec Gmbh Procédé d'expansion de cellules tueuses naturelles
WO2018161026A1 (fr) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions d'il-15 et méthodes pour immunothérapie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140120072A1 (en) * 2011-06-24 2014-05-01 Tella, Inc Method for amplifying nk cells
WO2015154012A1 (fr) * 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations
WO2017037083A1 (fr) * 2015-09-04 2017-03-09 Miltenyi Biotec Gmbh Procédé d'expansion de cellules tueuses naturelles
WO2018161026A1 (fr) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions d'il-15 et méthodes pour immunothérapie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIU ET AL.: "Growth and Activation of Natural Killer Cells Ex Vivo from Children with Neuroblastoma for Adoptive Cell Therapy", CLINICAL CANCER RESEARCH, vol. 19, no. 8, 15 April 2014 (2014-04-15), pages 2132 - 2143, XP055342076, doi:10.1158/1078-0432.CCR-12-1243 *
RUBNITZ ET AL.: "NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 6, 20 February 2010 (2010-02-20), pages 955 - 959, XP055310282, doi:10.1200/JCO.2009.24.4590 *
See also references of EP3746095A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504396B2 (en) 2016-12-21 2022-11-22 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
US12098388B2 (en) 2018-02-01 2024-09-24 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN114867847A (zh) * 2019-11-20 2022-08-05 吉爱希公司 用于培养自然杀手细胞的组合物及使用其来生产自然杀手细胞的方法
CN115197909A (zh) * 2021-04-12 2022-10-18 北京和斯瑞生物技术有限公司 一种nk细胞的体外培养方法
CN115197909B (zh) * 2021-04-12 2023-11-17 北京和斯瑞生物技术有限公司 一种nk细胞的体外培养方法
CN117106718A (zh) * 2023-09-21 2023-11-24 深圳泽医细胞治疗集团有限公司 一种靶向肺部的nk细胞培养基、培养方法与应用

Similar Documents

Publication Publication Date Title
AU2019215034B2 (en) Method of producing natural killer cells and composition for treating cancer
WO2019152663A1 (fr) Procédé de production de cellules tueuses naturelles et composition pour le traitement du cancer
KR20140092298A (ko) 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
JP2019504632A (ja) Ｎｋ細胞培養用培地添加キット、及びキットを用いるｎｋ細胞培養方法
US20230002731A1 (en) Method of producing natural killer cells and compositions thereof
JPWO2011030851A1 (ja) ナチュラルキラー細胞の製造方法
KR102236011B1 (ko) Nk 세포의 대량증식 배양방법
JP3904374B2 (ja) キラー活性を増強したリンパ球
WO2024015822A1 (fr) Méthode de traitement de la maladie de parkinson avec des cellules tueuses naturelles expansées
KR20190093500A (ko) Cd56+ 자연살해세포를 포함하는 항암용 조성물
KR20190093499A (ko) 자연살해세포의 생산방법
RU2780848C2 (ru) Способ получения природных клеток-киллеров и композиция для лечения рака
KR102032384B1 (ko) 제대혈 단핵세포에서의 자연살해세포의 제조 방법
KR100797050B1 (ko) 아토피성 피부염에 치료효과를 갖는 ｃｄ8 ｔ 세포
JP4106488B2 (ja) 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用
JPWO2005078072A1 (ja) Ｔ細胞免疫活性を調節する制御性細胞
CN116135969A (zh) 从外周血中扩增及产生细胞因子诱导的杀伤细胞群的方法
KR100797049B1 (ko) 아토피성 피부염에 치료효과를 갖는 ｃｄ4 ｔ 세포
RU2596505C1 (ru) Способ лечения онкологических больных цитотоксическими лимфоцитами
JP2021158935A (ja) 活性化されたキラー細胞を含むリンパ球の製造方法
Fujiwara et al. Graft-Versus-leukemia Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator–responder pairs
WO2003018784A1 (fr) Procede de production de lymphocytes t humains specifiques d'un antigene et medicaments associes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19746979

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3089853

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 140150140003000836

Country of ref document: IR

Ref document number: 139950140003004045

Country of ref document: IR

ENP Entry into the national phase

Ref document number: 2020541915

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019215034

Country of ref document: AU

Date of ref document: 20190131

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019746979

Country of ref document: EP

Effective date: 20200901

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020015512

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020015512

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200730

WWE Wipo information: entry into national phase

Ref document number: 520412566

Country of ref document: SA